SCHEMBL7180950

SCHEMBL7180950

CCOc1ccc(PC(=O)c2c(OC)cc(OC)cc2OC)c(C)c1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
MAPT P10636 4/20 0.42
TSHR P16473 3/20 0.42
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
HIF1A Q16665 1/20 0.40
CYP3A4 P08684 3/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 2/20 0.39
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
ATM Q13315 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182358 0.91 KMT2A (0.41) KMT2ATSHRMAPK1KDM4ESMN1; SMN2
SCHEMBL7175230 0.91 THRA (0.42) KMT2ATSHRMAPK1SMN1; SMN2LMNA
SCHEMBL7187068 0.90 SMN1; SMN2 (0.49) KMT2AMAPTTSHRMAPK1KDM4E
SCHEMBL7180673 0.90 KDM4E (0.45) KMT2AMAPTTSHRMAPK1KDM4E
SCHEMBL7189974 0.90 KMT2A (0.39) KMT2AMAPTMAPK1KDM4ESMN1; SMN2
SCHEMBL7187558 0.90 KMT2A (0.48) KMT2AMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL7180616 0.89 THRA (0.45) KMT2AMEN1GAA
SCHEMBL7186863 0.88 KMT2A (0.41) KMT2AMAPTMAPK1KDM4ESMN1; SMN2
Lithium SCHEMBL7180686 0.88 KDM4E (0.45) KMT2AMAPTTSHRMAPK1KDM4E
SCHEMBL7175053 0.88 THRA (0.47) TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MAPT 4870/4885TSHR 984/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MAPT 4859/4885TSHR 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.